ライフサイエンスコーパス: vasopressin

1 d by exposure to supraphysiological doses of vasopressin.

2 ccelerates its endocytosis in the absence of vasopressin.

3 s9) to identify PKA-independent responses to vasopressin.

4 relationship with the neuropeptide modulator vasopressin.

5 melanin-concentrating hormone, oxytocin, and vasopressin.

6 al ganglion cells expresses the neuropeptide vasopressin.

7 fy genes whose transcription is regulated by vasopressin.

8 he presence or absence of norepinephrine and vasopressin.

9 endothelin-1, gentamicin, norepinephrine and vasopressin.

10 Concealed vasopressin (0.03 U/min.) or norepinephrine infusions.

11 Treatment with IV 1-deamino-8-D-arginine vasopressin (0.4 ug/kg) + platelet transfusion (2 U) wit

12 ly led to a low single digit nanomolar human vasopressin 1a (hV1a) receptor antagonist 38.

13 of intranasal administration of an arginine vasopressin 1A and 1B receptor agonist against 1) no tre

14 en behavioral variation and variation in the vasopressin 1a receptor gene (Avpr1a) in bonobos.

15 ectivity versus the related receptors (human vasopressin 1a receptor, human vasopressin 1b receptor,

16 e attenuated by systemic pretreatment with a vasopressin-1a-receptor antagonist.

17 A2 area of the hippocampus, particularly the vasopressin 1b receptor (Avpr1b) expressed there, is nec

18 eptors (human vasopressin 1a receptor, human vasopressin 1b receptor, and human oxytocin receptor), a

19 ginine(8) vasopressin, dDAVP, 1) is a potent vasopressin 2 (V(2)) receptor (V(2)R) agonist approved i

20 12330A or the PKA inhibitor H89, but not the vasopressin 2 receptor (V(2)R) antagonist tolvaptan.

21 only a phosphorylated C-terminal tail of the vasopressin 2 receptor activates Src as efficiently as G

22 Tolvaptan, a vasopressin 2 receptor blocker, has been approved by reg

23 The oral vasopressin-2 receptor antagonist tolvaptan causes aquar

24 that resembles binding of the phosphorylated vasopressin-2 receptor tail to beta-arrestin-1.

25 ve focused on the neuropeptides oxytocin and vasopressin(4-6), which regulate aspects of social behav

26 s increased in PKA-null cells indicates that vasopressin activates one or more members of the AMPK/SN

27 Furthermore, the effect of IRAP to reduce vasopressin activity is a physiologically important cons

28 (adjusted odds ratio, 1.5; 95% CI, 1.3-1.8), vasopressin (adjusted odds ratio, 1.5; 95% CI, 1.1-2.1),

29 These activations weakened with oxytocin and vasopressin administration such that neural responses to

30 lls describing the response to V2R-selective vasopressin agonists and antagonists, the response to CR

31 Vasopressin agonists boosted placebo effects in women bu

32 Drugs (caffeine, theophylline) and hormones (vasopressin, aldosterone) known to exacerbate cysts elic

33 mes between standard dose of epinephrine and vasopressin alone or in combination with epinephrine.

34 ercentage of patients receiving epinephrine, vasopressin, amiodarone, lidocaine, atropine, bicarbonat

35 latter conferred responsiveness to arginine-vasopressin (an inhibitory PKC-dependent response).

36 We investigated whether the vasopressin-analog, terlipressin induces systemic vasoco

37 The vasopressin analogue desmopressin (desamino-d-arginine(8

38 Terlipressin is a synthetic vasopressin analogue that acts, via vascular vasopressin

39 ECV transfer and report that desmopressin, a vasopressin analogue, stimulated the uptake of fluoresce

40 ich when activated result in elevated plasma vasopressin and corticosterone.

41 The neuropeptides vasopressin and corticotropin-releasing factor facilitat

42 Patients who received vasopressin and its analogs had a reduced need for renal

43 In patients with distributive shock, vasopressin and its analogs use is associated with a red

44 In rodents, both vasopressin and oxytocin magnocellular neurones are osmo

45 Magnocellular vasopressin and oxytocin neurones in the rat hypothalamu

46 r isotocin, homologues of mammalian arginine vasopressin and oxytocin that are broadly implicated in

47 NCs, leading to a decrease in the release of vasopressin and oxytocin.

48 to 0.06 U/min) and hydrocortisone (n = 101), vasopressin and placebo (n = 104), norepinephrine and hy

49 are differences in plasma cytokine levels in Vasopressin and Septic Shock Trial for lactate less than

50 pinephrine group 28- and 90-day mortality in Vasopressin and Septic Shock Trial in lactate subgroups.

51 rates were 10-12 % higher than the original Vasopressin and Septic Shock Trial mortality.

52 In genotyped patients in the Vasopressin and Septic Shock Trial trial, we found that

53 In 632 patients enrolled in Vasopressin and Septic Shock Trial, Proprotein Convertas

54 essin versus norepinephrine and mortality in Vasopressin and Septic Shock Trial.

55 included genotyped patients enrolled in the Vasopressin and Septic Shock Trial.

56 l was applied to patients with AKI in VASST (Vasopressin and Septic Shock Trial; n = 271), and differ

57 mutant and wild-type mice had similar plasma vasopressin and solute excretion levels.

58 sistent with increased levels of circulating vasopressin and up-regulation of vasopressin V2 receptor

59 eptidergic neurons in the SCN: AVP (arginine vasopressin) and VIP (vasoactive intestinal polypeptide)

60 l copeptin production, a surrogate marker of vasopressin, and dependent on the experience of birth-re

61 Many SCN neurons express vasopressin, and it has been assumed that the role of va

62 a potential clinically important benefit for vasopressin, and larger trials may be warranted to asses

63 unctions, abnormalities in central oxytocin, vasopressin, and serotonin neurotransmission, and neuroi

64 in 1776 patients enrolled in the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study Wi

65 oc analysis was performed of the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study w

66 a early in patients selected for an enhanced vasopressin antagonism response.

67 Currently, vasopressin antagonists should not be offered routinely

68 By contrast, aquaretic drugs (such as vasopressin antagonists) predominantly cause water excre

69 Upon stimulation by vasopressin, AQP2 is phosphorylated at serine 256 (S256)

70 the endogenous IRAP substrates oxytocin and vasopressin are known to facilitate learning and memory.

71 ributing to those differences and identified vasopressin as a regulator of nestbuilding behaviour.

72 In cancer patients with septic shock, vasopressin as first-line vasopressor therapy was not su

73 esearch due to the therapeutic potentials of vasopressin as well as the possibility to systematically

74 vation of both oxytocin receptors (OXTR) and vasopressin (AVP) 1a receptors (AVPR1a).

75 we report that serotonin (5-HT) and arginine-vasopressin (AVP) act in opposite ways in the hypothalam

76 olocalization with the neuropeptide arginine vasopressin (AVP) and clock proteins (PER2 and BMAL1), s

77 nse to the neurohypophyseal hormone arginine vasopressin (AVP) and in the expression of oxidative str

78 Arginine vasopressin (AVP) and its type-2 receptor (V2R) play an

79 The neuropeptides vasopressin (AVP) and oxytocin (OT) have been implicated

80 s was dependent on the neuropeptide arginine vasopressin (AVP) because it was prevented by pharmacolo

81 Arginine-vasopressin (AVP) binding to vasopressin V2 receptors pr

82 ts, which contain a mutation in the arginine vasopressin (AVP) gene, exhibit lower behavioral arousal

83 Arginine vasopressin (AVP) has a key role in osmoregulation by fa

84 Prior studies show that oxytocin (Oxt) and vasopressin (Avp) have opposing actions on the skeleton

85 ts from a deficiency of the hormone arginine vasopressin (AVP) in the pituitary gland or the hypothal

86 ration of the "social" neuropeptide arginine vasopressin (AVP) is significantly lower in pediatric AS

87 accompanied by elevated circulating arginine vasopressin (AVP) levels in SHR-A3 compared with SHR-B2.

88 of the SCN, including VIP, GRP, and arginine vasopressin (AVP) neurons, with each ipRGC innervating s

89 asmatic nucleus output neuropeptide arginine-vasopressin (AVP) on the activity of preoptic area kissp

90 The neuropeptide arginine vasopressin (AVP) plays significant roles in maintaining

91 a self-assembling lipidized peptide arginine vasopressin (AVP) receptor agonist, that had not been de

92 Synthetic arginine vasopressin (AVP) receptor agonists able to induce syste

93 Arginine vasopressin (AVP) regulates fluid balance and blood pres

94 ogy of thirst, taste for water, and arginine-vasopressin (AVP) release: ( a) Thirst and AVP release a

95 Arginine vasopressin (AVP) stimulates the release of enteroendocr

96 iciency of the antidiuretic hormone arginine vasopressin (AVP) underlies diabetes insipidus, which is

97 al three distinct binding sites for arginine vasopressin (AVP) within its V2 -receptor (V2 R).

98 Here we show that arginine vasopressin (AVP), a neuropeptide that mediates complex

99 ncy and preschool, assayed oxytocin (OT) and vasopressin (AVP), and measured coparenting and child be

100 of copeptin, a surrogate marker of arginine vasopressin (AVP), to be associated with increased risk

101 ause cAMP is a central modulator of arginine vasopressin (AVP)-induced water transport in the renal c

102 e with a reduction of parvocellular arginine vasopressin (AVP)-positive neurons in the preoptic area,

103 PDE4 caused a greater increase in basal and vasopressin (AVP)-stimulated cAMP levels and Cl(-) secre

104 first study that demonstrates that arginine vasopressin boosts placebo effects and that the effect o

105 id not detect major deficiencies in arginine vasopressin [Ca(2+)](i) signaling in split-opened collec

106 Vasopressin cannot correct paracellular water loss in Il

107 Arginine vasopressin colocalized with EGFP more often in females

108 g adults with septic shock, the early use of vasopressin compared with norepinephrine did not improve

109 In VASST, vasopressin compared with norepinephrine was associated

110 gnetic resonance imaging, and serum arginine vasopressin concentration) were compatible with a diagno

111 he aim of this study was to evaluate whether vasopressin could be superior to norepinephrine to impro

112 In response to 1-desamino-8-D-arginine vasopressin (DDAVP), peak VWF:Ag levels exceeded 100 IU/

113 nalogue desmopressin (desamino-d-arginine(8) vasopressin, dDAVP, 1) is a potent vasopressin 2 (V(2))

114 controls AQP2 apical membrane abundance in a vasopressin-dependent manner, allowing for urine volume

115 oosts placebo effects and that the effect of vasopressin depends upon a significant sex by treatment

116 e to sepsis-induced immunoparalysis, whereas vasopressin does not have untoward immunologic effects.

117 ropin-releasing hormone-dominant to arginine vasopressin-dominant, and cortisol levels remain raised

118 Vasopressin exerted no immunomodulatory effects across t

119 were randomized to receive norepinephrine or vasopressin followed by hydrocortisone or placebo.

120 ong evidence suggests that certain hormones (vasopressin), foods (fructose), and metabolic products (

121 untered by intensivists who regularly employ vasopressin for the treatment of vasoplegic shock.

122 ctivity-dependent somatodendritic release of vasopressin from paraventricular nucleus neurones.

123 iased modulation is mediated by oxytocin and vasopressin G-protein-coupled receptors.

124 other GPCR agonists, including ADP, arginine vasopressin, glucagon-like peptide 1, and forskolin, and

125 ctor, dynorphin, norepinephrine, hypocretin, vasopressin, glucocorticoids, and neuroimmune factors) i

126 (interquartile range [IQR], 1 to -24) in the vasopressin group and 13 days (IQR, 1 to -25) in the nor

127 e was observed in 71 patients (56.8%) in the vasopressin group and 66 patients (52.8%) in the norepin

128 ailure was 94 of 165 patients (57.0%) in the vasopressin group and 93 of 157 patients (59.2%) in the

129 less use of renal replacement therapy in the vasopressin group than in the norepinephrine group (25.4

130 s (10.7%) had a serious adverse event in the vasopressin group vs 17 of 204 patients (8.3%) in the no

131 Vasopressin has achieved common usage for the treatment

132 The neuropeptide vasopressin has an important role in this entrainment.

133 as implicated the neuropeptides oxytocin and vasopressin in the modulation of human neural activity u

134 in, and it has been assumed that the role of vasopressin in the SCN reflects the activity of these ce

135 We have discovered that vasopressin-independent facets of this homeostatic mecha

136 genic hormones, including catecholamines and vasopressin, induce frequency-modulated cytosolic Ca(2+)

137 Vasopressin-induced aquaporin-2 phosphorylation within t

138 xiety and cortisol levels showed the largest vasopressin-induced modulation of placebo effects, sugge

139 ICU patients with septic shock who received vasopressin infusion added to at least one concomitant v

140 diabetes insipidus after discontinuation of vasopressin infusion among patients treated with vasopre

141 diabetes insipidus after discontinuation of vasopressin infusion among patients with septic shock as

142 diabetes insipidus after discontinuation of vasopressin infusion appears not to be a rare phenomenon

143 pressin infusion among patients treated with vasopressin infusion for shock.

144 of patients receiving norepinephrine but not vasopressin infusion for treatment of shock, criteria fo

145 diabetes insipidus after discontinuation of vasopressin infusion had undergone cardiothoracic interv

146 diabetes insipidus after discontinuation of vasopressin infusion have been published; the majority o

147 diabetes insipidus after discontinuation of vasopressin infusion remains to be elucidated but may in

148 diabetes insipidus after discontinuation of vasopressin infusion was 1.53% among all patients.

149 yscus and chemogenetics in Mus, we show that vasopressin inhibits nest building but not other parenta

150 ollecting duct; is modulated in abundance by vasopressin; interacts with aquaporin-2 (AQP2), Hsp70, a

151 Here we show that vasopressin is also expressed in many retinal cells that

152 d to differences in nest-building behaviour, vasopressin is differentially expressed in the hypothala

153 pig neonate demonstrated that the effect of vasopressin is not dependent on the level of maturation

154 Vasopressin levels begin to fall within minutes of water

155 thetic nervous system activity, and elevated vasopressin levels.

156 developed polyuria despite elevated arginine vasopressin levels.

157 own insect neuropeptides except for arginine-vasopressin-like peptide (AVLP), CNMamide, neuropeptide-

158 Vasopressin lowered mortality versus norepinephrine if l

159 Previous trials suggest that vasopressin may improve outcomes in patients with vasodi

160 twork describing PKA signaling that explains vasopressin-mediated regulation of membrane trafficking

161 Vasopressin-mediated regulation of renal water excretion

162 r genes, consistent with the conclusion that vasopressin-mediated transcriptional regulation is highl

163 e how intranasally administered oxytocin and vasopressin modulated neural activity when receiving neg

164 We localized a subpopulation of excitatory vasopressin neurons in the anterior hypothalamus that ma

165 ensitive neurons in the lamina terminals and vasopressin neurons in the paraventricular nucleus of th

166 nts of genetically identified neuroendocrine vasopressin neurons show they can anticipate osmotic cha

167 terminalis also resulted in Fos induction in vasopressin neurons within the PVN and supraoptic nucleu

168 activity (Normal: p < 0.001; HF: p < 0.05), vasopressin (Normal: p < 0.001; HF: p < 0.01), and cycli

169 The effects of vasopressin on expectancy-induced analgesia were signifi

170 sing; however, the influence of oxytocin and vasopressin on neural activity elicited during negative

171 ur results show effects of both oxytocin and vasopressin on the brain network involved in negative so

172 repinephrine and the alternative vasopressor vasopressin on the immune response and host defense.Meth

173 e liver with physiological concentrations of vasopressin only will evoke localized cytosolic calcium

174 Patients were assigned to either vasopressin or norepinephrine as first-line vasopressor

175 ess than or equal to 2 mmol/L, randomized to vasopressin or norepinephrine.

176 eleasing hormone and do not express arginine vasopressin or oxytocin.

177 responses were provoked by stimulation with vasopressin or serum.

178 ized to a 5-hour infusion of norepinephrine, vasopressin, or saline and intravenously challenged with

179 luenced response to either norepinephrine or vasopressin, or to corticosteroids in septic shock.

180 We isolated the insect oxytocin/vasopressin orthologue inotocin from the black garden an

181 e social behavior have mainly focused on the vasopressin-oxytocin family.

182 ntagonism acting on loci within the arginine vasopressin-oxytocin pathway explains how genetic divers

183 ted to gain novel insights into the oxytocin/vasopressin peptide-receptor interaction, which led to t

184 Treatment with 1-deamino-8-D-arginine vasopressin + platelet transfusion was not associated wi

185 for the clearance of misfolded pro-arginine vasopressin (proAVP) in the ER.

186 nd functional analysis of thirst neurons and vasopressin-producing neurons.

187 Reciprocally, Gs enhances IP1 through vasopressin receptor (V1A-R) but not alpha1 adrenergic r

188 VPA exposure downregulated prefrontal cortex vasopressin receptor (V1aR) and methyl CpG-binding prote

189 tissues through the inhibition of the type-2 vasopressin receptor (V2R) constitutes a validated strat

190 Here we demonstrate that a vasopressin receptor (V2R) mutant with truncated third i

191 Expression of arginine vasopressin receptor 1a (Avpr1a) and oxytocin receptor (

192 ingle 20 mg intravenous dose of the arginine vasopressin receptor 1A (V1a) antagonist, RG7713, on exp

193 treatment of mpkCCD14 cells with the type 2 vasopressin receptor agonist dDAVP increased mRNA and pr

194 Vasopressin receptor antagonists, urea, and loop diureti

195 expression variations of the oxytocin and/or vasopressin receptor genes OXTR and AVPR1A, respectively

196 e value in testing medications targeting the vasopressin receptor in high stress, alcohol-dependent p

197 selected for greater potential benefit from vasopressin receptor inhibition, tolvaptan was not assoc

198 n important role for development of oxytocin/vasopressin receptor modulators that would enable clear

199 In the present study, we show that vasopressin receptor type-2 (V2R) is localized to cilia

200 First, the vasopressin receptor-2 agonist, dDAVP, was delivered to

201 lial cells expressing the Galphas-coupled V2 vasopressin receptor.

202 Vasopressin receptors appear to have a regulatory role i

203 zation of the parathyroid hormone and type 2 vasopressin receptors.

204 properties on the insect and human oxytocin/vasopressin receptors.

205 The analysis revealed only 35 vasopressin-regulated genes (of 3659) including Aqp2.

206 These data are consistent with vasopressin-regulated uptake of ECVs in vivo We conclude

207 Vasopressin regulates phosphorylation at four sites with

208 Vasopressin regulates renal water excretion by binding t

209 These anticipatory signals for thirst and vasopressin release concentrate on the same homeostatic

210 Light-evoked vasopressin release contributes to the responses of SCN

211 Light-induced vasopressin release enhances the responses of SCN neuron

212 sepsis features impaired thirst and enhanced vasopressin release, the basis for these defects is unkn

213 nabled a distinctive regulation of pituitary vasopressin release.

214 which increases histone H3K27 acetylation of vasopressin-responsive genes (confirmed by ChIP-seq).

215 otic stress, posterior pituitary-projecting, vasopressin-secreting neurons (VPpp neurons) counter osm

216 tinct cellular processes to regulate thirst, vasopressin secretion and autonomic function.

217 Osmotically stimulated vasopressin secretion promotes antidiuresis while oxytoc

218 xtracellular osmolarity stimulate thirst and vasopressin secretion through a central osmoreceptor; ho

219 ey forebrain neurons that control thirst and vasopressin secretion.

220 other osmolytes readily stimulate thirst and vasopressin secretion.

221 Alternatives such as vasopressin/selepressin, angiotensin II, and phenylephri

222 In contrast, vasopressin, serotonin, and testosterone play only limit

223 hage studies, adjunct 1-deamino-8-D-arginine vasopressin showed no benefit in limiting hematoma expan

224 have been made available online for modeling vasopressin signaling and signaling downstream from othe

225 Vasopressin signaling is initiated by binding to a G-pro

226 The results show that V2R-mediated vasopressin signaling is predominantly, but not entirely

227 n mouse collecting duct cells to ask whether vasopressin signaling selectively increases Aqp2 gene tr

228 ice to discover an important contribution of vasopressin signaling to the evolution of nest building.

229 -like 3 by PKC or PKA downstream of AngII or vasopressin signaling, respectively, abrogates binding.

230 rvation of the 600-million-year-old oxytocin/vasopressin signalling system.

231 Here, we show that arginine vasopressin specifically activates interneurons to suppr

232 ng PKA, treatment with antidiuretic hormone (vasopressin) stimulated within 5-minutes proteasomal act

233 level in wild-type mice but does not restore vasopressin-stimulated levels of urea permeability.

234 model predicts that, through PKA activation, vasopressin stimulates AQP2 exocytosis by inhibiting MAP

235 also predicts that, through PKA activation, vasopressin stimulates Aqp2 transcription through induct

236 Since vasopressin stimulates renal water and sodium reabsorpti

237 was similar to levels in wild-type mice, but vasopressin stimulation of urea permeability in wild-typ

238 During perfusion with subthreshold vasopressin, sympathetic stimulation converted asynchron

239 pothalamus (PVN) that appear to synapse onto vasopressin-synthesizing neurons.

240 ediated inhibition of oxytocin- and arginine-vasopressin-synthesizing paraventricular nucleus (PVN) m

241 thin the domain of social communication, the vasopressin system is implicated in social cognition and

242 o effects by targeting pharmacologically the vasopressin system, characterized by a sexually dimorphi

243 ease of cross-reactivity with its correlated vasopressin system.

244 We used optogenetics to excite vasopressin terminals, originating from the hypothalamic

245 ultured cells that indicates aldosterone and vasopressin, the two major hormones regulating sodium re

246 different clinical outcomes and responses to vasopressin therapy.

247 ated by the neurohypophyseal peptide hormone vasopressin through actions in renal collecting duct cel

248 Patients were randomly allocated to vasopressin (titrated up to 0.06 U/min) and hydrocortiso

249 ounts for the ability of the peptide hormone vasopressin to regulate water excretion via a phosphoryl

250 ugh these findings do not support the use of vasopressin to replace norepinephrine as initial treatme

251 We compared vasopressin-to-norepinephrine group 28- and 90-day morta

252 ctivity of the net transcriptional response, vasopressin treatment was associated with increased RNA

253 tor with the C-terminal tail of the arginine vasopressin type 2 receptor (beta(2)V(2)R).

254 mbrane-delimited G protein-coupled receptor (vasopressin type 2 receptor; V(2)R) and a cytosolic prot

255 In this study, we examined whether vasopressin type-2 receptor (V2R) activity in cystic epi

256 vasopressor in septic shock; however, early vasopressin use has been proposed as an alternative.

257 onists to determine the role of oxytocin and vasopressin V(1a) receptors.

258 tin recruitment to the angiotensin AT(1) and vasopressin V(2) receptors.

259 vasopressin analogue that acts, via vascular vasopressin V1 receptors, as a systemic vasoconstrictor.

260 Selepressin, a selective vasopressin V1a receptor agonist, is a noncatecholaminer

261 olished by pretreatment of the RVLM with the vasopressin V1a receptor antagonist, SR 49059 (-1 +/- 1

262 t vascular tone through interaction with the vasopressin V1a receptor but that [Pyr(1) ]apelin-13-ind

263 activated the insect inotocin and the human vasopressin V1b receptors, but inhibited the human V1aR.

264 iven fluid secretion (PDE3), and response to vasopressin V2 receptor activation (both).

265 mice before and after administration of the vasopressin V2 receptor antagonist tolvaptan.

266 hanistic implications on the emerging use of vasopressin V2 receptor antagonists such as tolvaptan as

267 vated betaarr1 upon its interaction with the vasopressin V2 receptor C-terminal phosphopeptide (V2Rpp

268 circulating vasopressin and up-regulation of vasopressin V2 receptors in ADPKD.

269 Arginine-vasopressin (AVP) binding to vasopressin V2 receptors promotes redistribution of the

270 tream from a G-protein-coupled receptor, the vasopressin V2 subtype receptor, and its role of the reg

271 atinine clearance, >/=60 ml per minute), the vasopressin V2-receptor antagonist tolvaptan slowed the

272 definition (lactate > 2 mmol/L) differ from vasopressin versus norepinephrine and mortality in Vasop

273 Our first hypothesis was that the vasopressin versus norepinephrine comparison and 28-day

274 gnificantly (p = 0.028) lower mortality with vasopressin versus norepinephrine in lactate less than o

275 variants were further assessed in the VASST (Vasopressin versus Norepinephrine Infusion in Patients w

276 St Paul's Intensive Care Unit 2 (n=203), and Vasopressin Versus Norepinephrine Infusion in Patients W

277 d a continuous infusion of norepinephrine or vasopressin via microosmotic pumps and were challenged w

278 y and control the synthesis and secretion of vasopressin (VP) and oxytocin (OT) by the neurohypophysi

279 y of activity-dependent dendritic release of vasopressin (VP) from hypothalamic neurones in brain sli

280 escribe a critical role for the neuropeptide vasopressin (VP) in social buffering of synaptic metapla

281 (AQP2) is crucial for water homeostasis, and vasopressin (VP) induces AQP2 membrane trafficking by in

282 units (alpha, beta and gamma) are located in vasopressin (VP) magnocellular neurons in the hypothalam

283 Because vasopressin (VP) neurons play a pivotal role in coordina

284 s insipidus (NDI) is caused by impairment of vasopressin (VP) receptor type 2 signaling.

285 Here, we show that local vasopressin (VP) signaling in PVN buffers the short-term

286 ABSTRACT: Oxytocin (OT)- and vasopressin (VP)-secreting magnocellular neurons of the

287 than in the norepinephrine group (25.4% for vasopressin vs 35.3% for norepinephrine; difference, -9.

288 ized clinical trial in septic shock (VANISH [Vasopressin vs. Norepinephrine as Initial Therapy in Sep

289 Somatodendritic release of vasopressin was rarely observed during continuous firing

290 ich has been linked to nonosmotic release of vasopressin) was assessed.

291 een pSTAT5 and vesicular GABA transporter or vasopressin were observed, whereas approximately 20% and

292 gned to mimic the N terminus of oxytocin and vasopressin, were assessed and compared based on their a

293 ased on norepinephrine equivalents excluding vasopressin, were significantly lower at 24 hours in the

294 physiological concentrations of glucagon and vasopressin, where glucagon also facilitated the recruit

295 c perturbations by altering their release of vasopressin, which controls renal water excretion.

296 Vasopressin, which is a nonapeptide with substantial str

297 lly, we observed robust induction of NHA2 by vasopressin, which is physiologically consistent with in

298 tem inhibitor therapy versus those receiving vasopressin who were not on chronic renin-angiotensin-al

299 pressure in septic shock patients receiving vasopressin who were on chronic renin-angiotensin-aldost

300 response in septic shock patients receiving vasopressin who were on chronic renin-angiotensin-aldost